Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on March 13, 2026. The filing was submitted on March 16, 2026. The transaction was executed through BNP Paribas SA as part of the Company's existing share buyback programme, pursuant to a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 445,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,027.00 GBp; highest price paid was 2,060.00 GBp.
- Average Price: Volume-weighted average price paid was 2,041.70 GBp.
- Treasury Holdings: Following this purchase, the Company holds 249,816,503 ordinary shares in treasury.
- Shares in Issue: 4,066,354,262 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.14% of the total voting rights.
Material Changes
Since the commencement of the current buyback agreement on February 17, 2026, the Company has purchased an aggregate of 9,925,409 ordinary shares. The March 13 transaction increased the total treasury share count to 249,816,503. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025. No unusual items or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the total remaining authorization under the current buyback programme announced on February 17, 2026.
- Confirm the impact of the 6.14% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the uncertainties affecting the buyback programme.
- Check subsequent filings for updates on the aggregate number of shares purchased under the non-discretionary agreement.